BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260817T110000
DTEND;TZID=America/New_York:20260817T123000
DTSTAMP:20260812T221156
CREATED:20260804T165353Z
LAST-MODIFIED:20260811T202757Z
UID:10001771-1786964400-1786969800@lifescievents.com
SUMMARY:Insight Molecular Diagnostics Virtual KOL Event: Moving Toward In-House Heart Transplanted Organ Rejection Testing
DESCRIPTION:Join Insight Molecular Diagnostics (iMDx) for a virtual key opinion leader (KOL) event featuring Max Jacob Liebo\, MD (Loyola University Medical Center)\, who will join Nick Ioannou\, MD\, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO)\, to discuss the Company’s GraftAssure platform\, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring. \nThe event will provide an overview of GraftAssure\, currently under review by the FDA to be commercialized in kitted form for labs to test patients for kidney transplant rejection. Dr. Liebo will discuss how a kitted GraftAssure test (GraftAssureDx) can be used for in-house heart transplant rejection monitoring\, as well as implications for the industry and patients. \nA live question and answer session will follow. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/iag87wq/.
URL:https://lifescievents.com/event/iag87wq/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Events-Banners_2-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260819T110000
DTEND;TZID=America/New_York:20260819T123000
DTSTAMP:20260812T221156
CREATED:20260727T160423Z
LAST-MODIFIED:20260803T150501Z
UID:10001760-1787137200-1787142600@lifescievents.com
SUMMARY:Tvardi Therapeutics KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape
DESCRIPTION:Join Tvardi Therapeutics for a virtual key opinion leader (KOL) webinar featuring Randy Longman\, MD\, PhD (Weill Cornell Medicine)\, who will join Tvardi management to discuss the current treatment landscape in ulcerative colitis (UC) and the persistent unmet needs that remain despite recent clinical advances and currently approved therapies. \nThe event will feature new data from Tvardi and a review of the Phase 1 healthy volunteer results supporting the potential of TTI-109 in UC. The discussion will explore the scientific rationale for targeting STAT3\, a convergent node implicated in multiple pathways that contribute to the pathogenesis and persistence of UC. Tvardi management will also discuss the planned clinical development strategy for TTI-109. \nDr. Longman will provide his perspective on the clinical relevance of the findings and how a STAT3 inhibitor could ultimately fit within the UC treatment paradigm. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/yq052il/.
URL:https://lifescievents.com/event/yq052il/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/Tvardi-Banner-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260901T100000
DTEND;TZID=America/New_York:20260901T113000
DTSTAMP:20260812T221156
CREATED:20260708T124637Z
LAST-MODIFIED:20260811T134534Z
UID:10001751-1788256800-1788262200@lifescievents.com
SUMMARY:Dogwood Therapeutics Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapeutic Induced Neuropathic Pain (CINP)
DESCRIPTION:Join Dogwood Therapeutics for a virtual key opinion leader (KOL) event featuring J. Mark Joyce\, M.D. (CNS Healthcare)\, Iain D. Dukes\, D.Phil. (OrbiMed Advisors\, Chair Dogwood SAB)\, and Jerry Evarts\, Ph.D. (expert CMC Specialist\, Dogwood)\, who will join company management to discuss the unmet need and current treatment landscape for chemotherapeutic induced neuropathic pain (CINP). \nThe event will review the novel role of the Nav 1.7 sodium ion channel in pain signaling\, which is key to the initiation and conduction of the electrical signals that the brain interprets as pain. Management will discuss Halneuron®’s selective and differentiated Nav 1.7 mechanism of action as compared to current and future Nav inhibitors. The speakers will also review prior Halneuron pre-clinical and clinical research and the design and projected treatment outcomes of the ongoing Phase 2b CINP study design. Halneuron has been tested on more than 800 patients to date\, including patients suffering from cancer related pain and CINP. Guest experts will discuss ion channel therapies as a newer approach to treating chronic pain\, as well as the existing unmet medical need in treating CINP. The company will provide blinded interim results from the ongoing Phase 2b clinical trial in patients with a mean duration of five years of neuropathy due to their prior chemotherapy treatment\, and discuss the advancement of the first ever synthetic formulation of Tetrodotoxin to support Halneuron®’s’ Phase 3 development. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/tj25pyh4/.
URL:https://lifescievents.com/event/tj25pyh4/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/Dogwood-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260901T110000
DTEND;TZID=America/New_York:20260901T123000
DTSTAMP:20260812T221156
CREATED:20260720T123835Z
LAST-MODIFIED:20260811T142020Z
UID:10001753-1788260400-1788265800@lifescievents.com
SUMMARY:Fractyl Health Virtual Commercial Day: The Path to Commercializing Revita®\, the Potential First Procedural Therapy for Post-GLP-1 Weight Maintenance
DESCRIPTION:Join Fractyl Health’s management team to discuss the commercial opportunity and go-to-market strategy for Revita®\, following the Company’s positive one-year randomized data from the REMAIN-1 Midpoint Cohort — the first randomized\, sham-controlled evidence that a single Revita procedure can maintain up to 84% of prior GLP-1-induced weight loss one year after drug discontinuation\, when an adequate dose is delivered. \nAn estimated 40 million U.S. adults are currently on GLP-1 therapy — and Revita is designed to be their durable\, one-time procedural off-ramp when they stop. Ahead of the anticipated early Q4 2026 six-month topline readout of the REMAIN-1 Pivotal Cohort\, Fractyl’s management team will discuss the market opportunity for Revita\, its plans for bringing the therapy to patients and providers\, the reimbursement path ahead\, and the Company’s potential FDA De Novo marketing application submission anticipated in late Q4 2026. Together\, these milestones mark Fractyl’s transition from clinical proof to commercial execution. \nA live Q&A session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/ek248gc/.
URL:https://lifescievents.com/event/ek248gc/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/webp:https://lifescievents.com/wp-content/uploads/2026/07/Fractyl-Health-Banner.webp
END:VEVENT
END:VCALENDAR